1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
REGULATORY
Chuikyo Wants Sakigake Premium Review as a Package with Regulatory Reform
A Japanese reimbursement policy panel on October 20 continued to discuss the evaluation of patented medicines towards the FY2024 drug pricing reform. To stem the trend of drug lags and losses, many members called for reviewing the current sakigake premium…
To read the full story
REGULATORY
- Japan Cabinet OKs 5-Year Healthcare Strategy from FY2025
February 19, 2025
- Minister Touts “Balanced” Off-Year Revision after USCC Letter
February 19, 2025
- Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
- “Annual Reports” Allowed for CMC Changes with Minimal Impact: MHLW
February 17, 2025
- Japan to Approve EquMet Generics, More Copycats toward June Listing
February 17, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…